高级检索
当前位置: 首页 > 详情页

MicroRNA-30a suppresses the proliferation, migration and invasion of human renal cell carcinoma cells by directly targeting ADAM9

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Urology, Cangzhou Central Hospital, Cangzhou, Hebei 061110 [2]Department of Urology,Hebei Medical University Fourth Hospital [3]Department of Oncology,Shijiazhuang City No. 1 People's Hospital, Shijiazhuang, Hebei 050011, P.R. China
出处:
ISSN:

关键词: microRNA-30a renal cell carcinoma a disintegrin and metalloproteinase 9 progression

摘要:
An increasing number of studies reported that microRNA (miR)-30a was dysregulated in several types of human cancer and may contribute to cancer carcinogenesis and progression. However, its expression and roles in renal cell carcinoma (RCC) remain unknown. In the present study, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to quantify miR-30a expression in RCC tissues and cell lines. The cell counting kit-8 assay, migration and invasion assays were used to evaluate the roles of miR-30a on the proliferation, migration and invasion of RCC cells. The target gene of miR-30a was identified by luciferase reporter assays, RT-qPCR and western blotting. The results indicated that miR-30a was downregulated in RCC tissues and cell lines compared with corresponding noncancerous tissues and normal renal cell line, respectively. Re-expression of miR-30a inhibited the proliferation, migration and invasion of RCC cells. Additionally, ADAM metallopeptidase domain 9 (ADAM9) was validated as a direct target of miR-30a. Furthermore, the knockdown of ADAM9 by small interfering RNAs was able to mimic the effects of miR-30a overexpression in RCC cells. These results highlight the important role for miR-30a in the occurrence and development of RCC, and the restoration of miR-30a might be investigated as a potential strategy for treating RCC.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2018]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q4 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Urology, Cangzhou Central Hospital, Cangzhou, Hebei 061110
通讯作者:
通讯机构: [2]Department of Urology,Hebei Medical University Fourth Hospital [*1]Department of Urology, Hebei Medical University Fourth Hospital, 12 Jiankang Road, Shijiazhuang, Hebei 050011, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39767 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号